Literature DB >> 6787119

Monoclonal antibodies to two determinants of melanoma-antigen p97 act synergistically in complement-dependent cytotoxicity.

I Hellström, J P Brown, K E Hellström.   

Abstract

Microcytotoxicity tests were used to study complement-dependent cytotoxicity of 2 monoclonal IgG2a antibodies, 96.5 and 118.1, both alone and in combination. These antibodies are specific for 2 antigenic determinants, p97a and p97b, respectively, of p97, a cell-surface glycoprotein present on most human melanomas and, in smaller amounts, on other tumors and normal tissues. For 10 of 12 melanoma lines, complement-dependent cytotoxicity was much greater in the presence of both antibodies than with either antibody alone. Synergism was not observed when the antibodies were tested in combination with an IgG2a antibody to a different cell-surface glycoprotein, nor was it detected in tests of 4 non-melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6787119

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

2.  Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy.

Authors:  K S Webb; J L Ware; S F Parks; W H Briner; D F Paulson
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 3.  Human tumor-associated antigens identified by monoclonal antibodies.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Springer Semin Immunopathol       Date:  1982

Review 4.  Immunotherapy with monoclonal antibodies in metastatic melanoma.

Authors:  T A Steffens; D F Bajorin; A N Houghton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  Comparative clinical pharmacology of [111In]-labeled murine monoclonal antibodies.

Authors:  M G Rosenblum; J L Murray; L Lamki; G David; D Carlo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen.

Authors:  G M Stuhlmiller; T L Darrow; D M Haupt; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 7.  Intratumor immunologic heterogeneity.

Authors:  F R Miller
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

Review 8.  Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting.

Authors:  R W Baldwin; M V Pimm
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

Review 9.  Diagnostic and therapeutic use of monoclonal antibodies to human tumor antigens.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

10.  Complement-dependent cytotoxicity of anti-human osteogenic sarcoma monoclonal antibodies.

Authors:  M R Price; M V Pimm; R W Baldwin
Journal:  Br J Cancer       Date:  1982-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.